Nevertheless, Adobe remains on a firm footing into 2025, supported by overall strong fundamentals and several factors positioning the stock to rebound. With shares trading near a 52-week low ...

Therefore, the Zacks rating upgrade for Sensei Biotherapeutics basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Adobe is making a ton of money growing its subscription revenue and quietly building an AI business that could be huge. Despite all this, the stock has been punished, dropping around 30% in the ...

Adobe (NASDAQ: ADBE) shareholders might wish they could use Photoshop, the tech giant's flagship image-editing tool, to magically erase the stock's disappointing performance in 2024. Despite solid ...

The stock hasn't performed well, but its software business keeps growing. In its fiscal year that ended on Nov. 29, 2024, total revenue rose 11% year over year. Adobe's bottom line is rising more ...